Overview

Brief Intervention to Reduce Fear of Public Speaking

Status:
Terminated
Trial end date:
2020-10-30
Target enrollment:
0
Participant gender:
All
Summary
The study will test the efficacy of propranolol or placebo, administered after retrieval of a previously acquired public speaking fear, in reducing fear and avoidance of public speaking.
Phase:
Phase 4
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
New York State Psychiatric Institute
Treatments:
Propranolol
Criteria
Inclusion Criteria:

- 18-60 years of age at the time of consent

- Principal Diagnosis of Social Anxiety Disorder, Performance only type

- Has clinically significant fear of public speaking

- Physically healthy

- If female, non-pregnant and not nursing

- Off all psychotropic drug for at least 4 weeks

- A level of understanding sufficient to provide written informed consent to all
required study tests and procedures.

Exclusion Criteria:

- History of other serious psychiatric disorder

- Current Major Depressive Disorder

- Presence of developmental disorder or intellectual disability

- SAD patients with SAD not of the performance only type

- Women who are pregnant or nursing

- Current use of psychiatric medication

- Current substance use disorder

- Persons planning to start another treatment during the study period.

- Any significant medical condition that might increase the risk or participation (e.g.,
seizure disorder, respiratory disorders [e.g., bronchial asthma], cardiovascular
disease [e.g., congestive heart failure, heart arrhythmias, sinus bradycardia and
greater than first degree block ], low blood pressure [ < 90/60], diabetes, liver or
kidney disorders)

- Use of medications that might negatively interact with propranolol (e.g., ACE
inhibitors; catecholamine depleting drugs, such as reserpine; calcium channel
blockers; digitalis glycosides; haloperidol; chlorpromazine; aluminum hydroxide gel;
phenytoin; phenobarbitone; rifampin; antipyrine; lidocaine; cimetidine; theophylline)